JP2006506441A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506441A5
JP2006506441A5 JP2004553936A JP2004553936A JP2006506441A5 JP 2006506441 A5 JP2006506441 A5 JP 2006506441A5 JP 2004553936 A JP2004553936 A JP 2004553936A JP 2004553936 A JP2004553936 A JP 2004553936A JP 2006506441 A5 JP2006506441 A5 JP 2006506441A5
Authority
JP
Japan
Prior art keywords
polypeptide
box
hmgb
use according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004553936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/036975 external-priority patent/WO2004046338A2/en
Publication of JP2006506441A publication Critical patent/JP2006506441A/ja
Publication of JP2006506441A5 publication Critical patent/JP2006506441A5/ja
Withdrawn legal-status Critical Current

Links

JP2004553936A 2002-11-20 2003-11-19 免疫応答を増大させるためのhmgbポリペプチドの使用 Withdrawn JP2006506441A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42784802P 2002-11-20 2002-11-20
PCT/US2003/036975 WO2004046338A2 (en) 2002-11-20 2003-11-19 Use of hmgb polypeptides for increasing immune responses

Publications (2)

Publication Number Publication Date
JP2006506441A JP2006506441A (ja) 2006-02-23
JP2006506441A5 true JP2006506441A5 (2) 2006-12-28

Family

ID=32326601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553936A Withdrawn JP2006506441A (ja) 2002-11-20 2003-11-19 免疫応答を増大させるためのhmgbポリペプチドの使用

Country Status (6)

Country Link
US (1) US20060121047A1 (2)
EP (1) EP1567544A4 (2)
JP (1) JP2006506441A (2)
AU (1) AU2003295653B2 (2)
CA (1) CA2505682A1 (2)
WO (1) WO2004046338A2 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
JP5225109B2 (ja) 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトhmgb−1に特異的に結合する抗体を有効成分として含有する治療剤
US8227417B2 (en) * 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
CN103097399A (zh) 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3229813B1 (en) 2014-12-12 2021-03-24 The Feinstein Institute for Medical Research Treatment of hmgb1-mediated inflammation
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CN108367049A (zh) 2015-12-11 2018-08-03 海德堡吕布莱希特-卡尔斯大学 Pkm2调节剂和hmgb1的组合制剂
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
US20250101204A1 (en) * 2022-02-28 2025-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for protecting against cell damage and inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
DE69737870T2 (de) * 1996-07-17 2008-02-07 Kaneka Corp. Medikamente für die diagnostik von autoimmunerkrankungen
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2001070663A2 (en) * 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN100447154C (zh) * 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
US20030014155A1 (en) * 2001-07-12 2003-01-16 Applied Material, Inc. High temperature substrate transfer robot

Similar Documents

Publication Publication Date Title
JP2006506441A5 (2)
Jahrsdörfer et al. CpG oligodeoxynucleotides as immunotherapy in cancer
KR101092043B1 (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
EP0855184A1 (en) Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
Tomai et al. TLR7/8 agonists as vaccine adjuvants
CA2412026A1 (en) Immunostimulatory rna/dna hybrid molecules
BRPI0010612B8 (pt) vacinas
ES3035198T3 (en) Cpg amphiphiles and uses thereof
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
Beignon et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells
JP2007508273A5 (2)
Xiang et al. Promising particle-based vaccines in cancer therapy
CA2523032A1 (en) Vaccines for cancer therapy
JP2002531521A5 (2)
TWI705972B (zh) 惡性病變的組合治療
JPH09511737A (ja) 免疫治療剤とその使用
Shi et al. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion
JP2003530088A5 (2)
JP2009544610A5 (2)
JP2006502228A5 (2)
AU2007266235A1 (en) Bioactive purified HspE7 compositions
Charoenvit et al. CEL-1000—a peptide with adjuvant activity for Th1 immune responses
Osorio et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization
KR102375057B1 (ko) Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물
AU2005220156B2 (en) Peptides of IL1 beta and TNF alpha and method of treatment using same